trending Market Intelligence /marketintelligence/en/news-insights/trending/m_wdv78o5p1h7oyd6s0koa2 content esgSubNav
In This List

OncoCyte to fund cancer test development through private placement

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


OncoCyte to fund cancer test development through private placement

OncoCyte Corp. completed a private placement with two of its current investors for initial gross proceeds of $8 million.

One of the investors has committed to purchase an additional $2 million worth of shares prior to April 30.

All in all, the Alameda, Calif.-based biotechnology company will issue 7,936,508 common shares for $1.26 apiece.

Oncocyte intends to use the net proceeds to fund the development of its liquid biopsy diagnostic tests for the early detection of cancer, among other things.